New Enterprise Associates

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

NODAR, Inc. is a Boston-based company that specializes in manufacturing advanced sensors for various transportation modes, including cars, trucks, drones, ships, trains, and aircraft. Established in 2018, NODAR focuses on developing cutting-edge camera-based 3D vision systems aimed at enhancing the safety and reliability of autonomous vehicles. Their flagship product, Hammerhead, utilizes off-the-shelf cameras to deliver long-range, ultra-precise depth sensing essential for Level 3 and Level 4 autonomous applications. This technology enables critical functionalities such as collision warning, path planning, and automatic emergency braking, while ensuring cost-effectiveness and high performance. NODAR's innovations target automotive, marine, and railway industries, providing solutions that meet the growing demand for reliable 3D sensing technology in the mainstream automotive market.

Proof of Learn is a talent marketplace focused on educating and placing the next generation of developers. Founded in 2021 and based in Boston, the company operates Metacrafters.io, a multichain learn-to-earn platform that teaches users how to write smart contracts and build on-chain applications. The platform aims to provide equal access to education and job opportunities in the emerging Web3 space, utilizing blockchain technology to create a decentralized model for learning. By empowering learners to gain skills, earn rewards, and secure employment, Proof of Learn addresses the growing demand for qualified talent in the digital economy.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Tulip Interfaces, Inc. specializes in creating applications for the manufacturing industry that enhance shop floor operations. Founded in 2012 and based in Somerville, Massachusetts, the company offers a no-code platform that allows organizations to integrate data from various sources, including sensors and existing equipment. This integration facilitates the creation of digital work instructions and provides real-time visibility into operations, including the performance of personnel and machinery. Tulip serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, helping companies improve productivity, quality, and operational efficiency. By leveraging advanced technologies such as intelligent hardware sensors, computer vision, and machine learning, Tulip's platform enables organizations to digitally transform their operations and achieve better end-to-end traceability.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Burrow, Inc. is a New York-based furniture company that designs, manufactures, and supplies a range of home furnishings, including customizable sofas, sectionals, loveseats, armchairs, and ottomans, as well as tables, rugs, and various accessories. Founded in 2016, Burrow focuses on creating luxury furniture that is both easy to move and comfortable, utilizing sustainably-sourced hardwood and non-toxic, scratch- and stain-resistant fabrics. The company aims to reinvent the home furnishing experience by offering personalized and durable products that allow customers to avoid traditional retail markups. Burrow sells its items through physical showrooms in several states, including Washington, Massachusetts, Texas, and California, as well as through its online platform. The company's manufacturing facility is located in Mexico City, Mexico.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Burrow, Inc. is a New York-based furniture company that designs, manufactures, and supplies a range of home furnishings, including customizable sofas, sectionals, loveseats, armchairs, and ottomans, as well as tables, rugs, and various accessories. Founded in 2016, Burrow focuses on creating luxury furniture that is both easy to move and comfortable, utilizing sustainably-sourced hardwood and non-toxic, scratch- and stain-resistant fabrics. The company aims to reinvent the home furnishing experience by offering personalized and durable products that allow customers to avoid traditional retail markups. Burrow sells its items through physical showrooms in several states, including Washington, Massachusetts, Texas, and California, as well as through its online platform. The company's manufacturing facility is located in Mexico City, Mexico.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.

Tulip Interfaces, Inc. specializes in creating applications for the manufacturing industry that enhance shop floor operations. Founded in 2012 and based in Somerville, Massachusetts, the company offers a no-code platform that allows organizations to integrate data from various sources, including sensors and existing equipment. This integration facilitates the creation of digital work instructions and provides real-time visibility into operations, including the performance of personnel and machinery. Tulip serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, helping companies improve productivity, quality, and operational efficiency. By leveraging advanced technologies such as intelligent hardware sensors, computer vision, and machine learning, Tulip's platform enables organizations to digitally transform their operations and achieve better end-to-end traceability.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Tiburio Therapeutics, Inc. is a biotechnology company focused on developing and manufacturing medicines for diseases related to the endocrine system. Founded in 2018 and based in Cambridge, Massachusetts, the company is advancing clinical-stage compounds aimed at treating rare neuroendocrine tumors and endocrine diseases. Notably, Tiburio is developing TBR-760, which targets non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule designed to shrink or halt tumor growth. Additionally, Tiburio is working on TBR-065 for other rare endocrine diseases, addressing significant patient needs in these underserved areas.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

Formlabs Inc. is a company that designs and manufactures advanced 3D printing systems targeted at engineers, designers, and artists. Established in 2011 and headquartered in Somerville, Massachusetts, Formlabs offers a diverse range of products, including the Form 3, Form 3B, and Form 3L printers, all utilizing Low Force Stereolithography (LFS) technology. The company also provides post-processing solutions such as Form Wash and Form Cure, as well as the Fuse 1 SLS 3D printer and the Form Cell manufacturing solution. Formlabs develops high-performance materials for various applications in industries like dental, healthcare, jewelry, and education. Its PreForm software facilitates the preparation of models for printing, making it a preferred choice among professionals worldwide. With additional offices in Germany, Japan, China, Singapore, Hungary, and North Carolina, Formlabs continues to innovate in the field of 3D printing, enhancing the capabilities of digital fabrication.

Tamr, Inc. is an enterprise data unification company that specializes in providing data management solutions. The company offers a platform that utilizes machine learning combined with human expertise to identify and integrate diverse internal and external data sources, thereby enabling organizations to manage siloed data effectively. Tamr's services include enterprise data preparation, clinical data conversion, procurement optimization, and customer data integration, catering to various sectors such as financial services, life sciences, government, and manufacturing. Founded in 2013 by experienced professionals in the database industry, Tamr is headquartered in Cambridge, Massachusetts, with additional offices in major cities including New York, Seattle, San Francisco, Washington, D.C., and London. The company aims to deliver valuable insights from data, supporting clients in achieving successful business outcomes.

Automation Anywhere, Inc. is a global leader in Robotic Process Automation (RPA), specializing in the development of AI-powered software solutions designed to enhance business efficiency. Founded in 2003 and headquartered in San Jose, California, the company offers a cloud-native platform that integrates RPA with artificial intelligence, machine learning, and analytics. Its flagship products include Automation Anywhere Enterprise, which automates IT and business processes; Automation Anywhere Server for streamlined business operations; and IQ Bot, a cognitive automation solution that addresses complex business tasks. Additionally, the company provides a comprehensive suite of testing tools, such as Testing Anywhere, which supports quality assurance across various platforms. Automation Anywhere also offers consulting services and collaborates strategically with Microsoft Azure. The company has expanded its presence internationally with offices in several major cities across the United States, Europe, the Middle East, and Asia.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Burrow, Inc. is a New York-based furniture company that designs, manufactures, and supplies a range of home furnishings, including customizable sofas, sectionals, loveseats, armchairs, and ottomans, as well as tables, rugs, and various accessories. Founded in 2016, Burrow focuses on creating luxury furniture that is both easy to move and comfortable, utilizing sustainably-sourced hardwood and non-toxic, scratch- and stain-resistant fabrics. The company aims to reinvent the home furnishing experience by offering personalized and durable products that allow customers to avoid traditional retail markups. Burrow sells its items through physical showrooms in several states, including Washington, Massachusetts, Texas, and California, as well as through its online platform. The company's manufacturing facility is located in Mexico City, Mexico.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing non-opioid and non-addictive therapies aimed at addressing chronic pain. The company's product pipeline includes CNTX-4975, currently in Phase III trials for moderate to severe knee osteoarthritis pain, and in Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials targeting chronic pain associated with inflammatory, neuropathic, and mixed conditions. Other candidates under development include CNTX-6970, for inflammatory pain, and CNTX-2022, a high-concentration topical gel formulation of lidocaine for various types of pain. CNTX-6016 is also in pre-clinical stages focusing on chronic neuropathic pain. Founded in 2013, Centrexion Therapeutics aims to provide safe and effective solutions for patients suffering from chronic pain conditions.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Desktop Metal, Inc. is a manufacturer of additive manufacturing solutions, specializing in 3D printing technologies for metal and carbon fiber. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System designed for office use, and the Fiber desktop 3D printer. Desktop Metal serves a variety of industries such as automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development. Its innovative systems, materials, and software facilitate on-demand digital mass production, providing the speed, cost-efficiency, and part quality necessary for modern manufacturing. The company markets its solutions across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with a significant portion of its revenue generated from the Americas.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Tulip Interfaces, Inc. specializes in creating applications for the manufacturing industry that enhance shop floor operations. Founded in 2012 and based in Somerville, Massachusetts, the company offers a no-code platform that allows organizations to integrate data from various sources, including sensors and existing equipment. This integration facilitates the creation of digital work instructions and provides real-time visibility into operations, including the performance of personnel and machinery. Tulip serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, helping companies improve productivity, quality, and operational efficiency. By leveraging advanced technologies such as intelligent hardware sensors, computer vision, and machine learning, Tulip's platform enables organizations to digitally transform their operations and achieve better end-to-end traceability.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

Desktop Metal, Inc. is a manufacturer of additive manufacturing solutions, specializing in 3D printing technologies for metal and carbon fiber. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System designed for office use, and the Fiber desktop 3D printer. Desktop Metal serves a variety of industries such as automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development. Its innovative systems, materials, and software facilitate on-demand digital mass production, providing the speed, cost-efficiency, and part quality necessary for modern manufacturing. The company markets its solutions across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with a significant portion of its revenue generated from the Americas.

ClearMotion, Inc. is an automotive technology company that specializes in developing advanced suspension systems to enhance vehicle comfort and handling. Founded out of MIT in 2008 and based in Billerica, Massachusetts, with operations in Nuneaton, United Kingdom, ClearMotion integrates hardware and software to create a proactive ride system that anticipates and counteracts shocks and vibrations from uneven road surfaces. This innovative technology not only improves ride quality but also enhances the overall user experience in vehicles. By mapping road surfaces in real-time, ClearMotion's system can mitigate the effects of road roughness almost instantaneously, ensuring a smoother ride for both drivers and passengers.

Docent Health, based in Cambridge, Massachusetts, develops an enterprise consumer engagement platform aimed at enhancing patient care. The company focuses on helping health systems build and maintain lasting relationships with patients by integrating advanced consumer technology and hospitality-inspired service. Its platform combines digital and human interactions to provide personalized support through real-time text messaging, ensuring that patients receive empathetic and tailored experiences related to their clinical care. By leveraging best practices from various industries, Docent Health seeks to promote customer-centric care, ultimately increasing patient lifetime value and assisting healthcare organizations in expanding their market share.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Desktop Metal, Inc. is a manufacturer of additive manufacturing solutions, specializing in 3D printing technologies for metal and carbon fiber. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System designed for office use, and the Fiber desktop 3D printer. Desktop Metal serves a variety of industries such as automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development. Its innovative systems, materials, and software facilitate on-demand digital mass production, providing the speed, cost-efficiency, and part quality necessary for modern manufacturing. The company markets its solutions across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with a significant portion of its revenue generated from the Americas.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Docent Health, based in Cambridge, Massachusetts, develops an enterprise consumer engagement platform aimed at enhancing patient care. The company focuses on helping health systems build and maintain lasting relationships with patients by integrating advanced consumer technology and hospitality-inspired service. Its platform combines digital and human interactions to provide personalized support through real-time text messaging, ensuring that patients receive empathetic and tailored experiences related to their clinical care. By leveraging best practices from various industries, Docent Health seeks to promote customer-centric care, ultimately increasing patient lifetime value and assisting healthcare organizations in expanding their market share.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

Desktop Metal, Inc. is a manufacturer of additive manufacturing solutions, specializing in 3D printing technologies for metal and carbon fiber. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System designed for office use, and the Fiber desktop 3D printer. Desktop Metal serves a variety of industries such as automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development. Its innovative systems, materials, and software facilitate on-demand digital mass production, providing the speed, cost-efficiency, and part quality necessary for modern manufacturing. The company markets its solutions across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with a significant portion of its revenue generated from the Americas.

Glamsquad, Inc., also known as GLAM Group, is a New York-based company that specializes in providing on-demand beauty services. Founded in 2013, Glamsquad offers a range of services including hair styling, makeup application, and nail care, catering to clients in major cities such as New York City, Los Angeles, Miami, Washington, D.C., Boston, and the San Francisco Bay Area. The company employs a network of trained and vetted beauty professionals who deliver personalized experiences for various occasions, including home appointments, parties, and weddings. Glamsquad leverages technology to facilitate easy booking through its app and website, ensuring clients can select services, schedule appointments, and enjoy the convenience of professional beauty care at home. In addition to services, Glamsquad has introduced its own line of hair and makeup products, designed to complement their offerings and meet client needs.

Acquia Inc., established in 2007, is a technology company based in Boston, Massachusetts, with an additional office in Pune, India. It specializes in developing and operating a cloud-based platform that empowers organizations to create, manage, and optimize digital experiences. Acquia's platform offers a range of solutions, including commerce, content, community, and contextual services, catering to diverse industries such as government, consumer brands, higher education, and more. Key products include Acquia Cloud, a Platform-as-a-Service for Drupal website creation and management; Acquia Lift for site templating; Acquia Content Hub for multi-channel content distribution; and Acquia Journey for data-driven customer journey creation. Acquia also provides web content management, security, commerce solutions, and technical support services. The company's platform enables organizations to accelerate time to market, enhance customer engagement, and deliver contextually relevant digital experiences across various channels.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing therapeutics for diseases associated with the overactivation of the complement system. Utilizing a peptide chemistry platform, the company creates synthetic macrocyclic peptides that combine the specificity of antibodies with the pharmacological advantages of small molecules. Its lead candidate, Zilucoplan, is an injectable treatment that has completed Phase II clinical trials for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria, along with a Phase Ib trial for patients with renal impairment. Additionally, Ra Pharmaceuticals is advancing pre-clinical programs targeting Factor D inhibition for C3 glomerulonephritis and other complement factors for various diseases. The company has established a collaboration with Merck & Co., Inc. to explore orally available cyclic peptides for non-complement cardiovascular targets. Founded in 2008, Ra Pharmaceuticals operates as a subsidiary of UCB SA.

Tamr, Inc. is an enterprise data unification company that specializes in providing data management solutions. The company offers a platform that utilizes machine learning combined with human expertise to identify and integrate diverse internal and external data sources, thereby enabling organizations to manage siloed data effectively. Tamr's services include enterprise data preparation, clinical data conversion, procurement optimization, and customer data integration, catering to various sectors such as financial services, life sciences, government, and manufacturing. Founded in 2013 by experienced professionals in the database industry, Tamr is headquartered in Cambridge, Massachusetts, with additional offices in major cities including New York, Seattle, San Francisco, Washington, D.C., and London. The company aims to deliver valuable insights from data, supporting clients in achieving successful business outcomes.

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics that target the disease-promoting microenvironment associated with fibrotic diseases and cancer. Established in 2011 and based in Waltham, Massachusetts, the company is engaged in creating pharmaceutical preparations aimed at diagnosing and treating oncological, tumor, and inflammatory diseases. XTuit Pharmaceuticals employs novel strategies to enhance cancer therapy by specifically addressing the tumor microenvironment. Its drug development pipeline includes innovative approaches that inhibit extracellular matrix synthesis and stabilize activated stromal cells, utilizing a clinical biomarker platform for effective treatment outcomes.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

GuideSpark, Inc. specializes in employee communication software aimed at enhancing engagement within organizations. Its primary offering, GuideSpark Communicate Cloud, allows human resource teams to implement communication campaigns and create multi-format content experiences that foster the adoption of HR programs. The platform addresses various HR challenges including benefits, performance management, and compensation. Additionally, GuideSpark provides resources for Total Rewards communication, talent management, and company culture communication, all designed to deepen employee appreciation for organizational investments and clarify their roles within the company. Founded in 2008 and headquartered in Redwood City, California, GuideSpark also has offices in Portland, Boston, San Francisco, and New York. The company serves over 1,000 enterprise customers, facilitating change communications that help align employee behavior with critical business objectives.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is advancing a pipeline of monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, targeting CD73; SRF617, aimed at CD39; SRF388, which targets interleukin 27; and SRF813, focused on CD112R. Additionally, Surface is exploring earlier-stage programs that address critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established collaborations with notable partners, including Novartis Institutes for Biomedical Research for cancer therapy development and Merck Sharp & Dohme Corp. to assess the safety and efficacy of combining SRF617 with KEYTRUDA, an anti-PD-1 therapy. Founded in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology aims to create conditions that enhance anti-tumor immune responses through its targeted approaches in cancer immunotherapy.

ClearMotion, Inc. is an automotive technology company that specializes in developing advanced suspension systems to enhance vehicle comfort and handling. Founded out of MIT in 2008 and based in Billerica, Massachusetts, with operations in Nuneaton, United Kingdom, ClearMotion integrates hardware and software to create a proactive ride system that anticipates and counteracts shocks and vibrations from uneven road surfaces. This innovative technology not only improves ride quality but also enhances the overall user experience in vehicles. By mapping road surfaces in real-time, ClearMotion's system can mitigate the effects of road roughness almost instantaneously, ensuring a smoother ride for both drivers and passengers.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

DataRobot, Inc. is a Boston-based company that specializes in developing an automated machine learning platform aimed at empowering enterprises to construct predictive models efficiently. Its offerings include DataRobot Cloud, a cloud-based platform for predictive analytics, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. Additionally, DataRobot Enterprise provides features tailored for large organizations, such as flexible deployment options, governance, and comprehensive support. The company's solutions cater to a diverse clientele, including business analysts, data scientists, executives, and IT professionals across various sectors such as banking, healthcare, and manufacturing. Founded in 2012, DataRobot has expanded its operations internationally, with locations in London, Paris, Kyiv, Tokyo, and Singapore, and maintains a strategic partnership with Snowflake to enhance its offerings.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Solace Therapeutics, Inc. is a medical device company focused on developing non-surgical treatments for common bladder disorders, including stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company offers the Vesair Bladder Control System, a lightweight device designed to float within the urinary bladder and effectively reduce involuntary urinary leakage. Solace Therapeutics aims to enhance patient quality of life by providing an office-based therapy that avoids the side effects often associated with traditional drug and surgical options. This innovative approach does not require anesthesia or significant lifestyle changes and is reversible at any time. Established in 2002, Solace Therapeutics is headquartered in Framingham, Massachusetts.

Acquia Inc., established in 2007, is a technology company based in Boston, Massachusetts, with an additional office in Pune, India. It specializes in developing and operating a cloud-based platform that empowers organizations to create, manage, and optimize digital experiences. Acquia's platform offers a range of solutions, including commerce, content, community, and contextual services, catering to diverse industries such as government, consumer brands, higher education, and more. Key products include Acquia Cloud, a Platform-as-a-Service for Drupal website creation and management; Acquia Lift for site templating; Acquia Content Hub for multi-channel content distribution; and Acquia Journey for data-driven customer journey creation. Acquia also provides web content management, security, commerce solutions, and technical support services. The company's platform enables organizations to accelerate time to market, enhance customer engagement, and deliver contextually relevant digital experiences across various channels.

Upskill, Inc. is a technology company specializing in augmented reality software tailored for the industrial workforce. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill offers the Skylight platform, which enables organizations to create applications for smart glasses. This platform connects workers across various industries—including healthcare, manufacturing, retail, and logistics—with essential information, processes, and tools, allowing them to perform tasks more efficiently and accurately. Upskill's solutions facilitate hands-free operation, thereby enhancing productivity, quality, and compliance in competitive environments. The company was previously known as APX Labs, LLC before rebranding in January 2017.

Tamr, Inc. is an enterprise data unification company that specializes in providing data management solutions. The company offers a platform that utilizes machine learning combined with human expertise to identify and integrate diverse internal and external data sources, thereby enabling organizations to manage siloed data effectively. Tamr's services include enterprise data preparation, clinical data conversion, procurement optimization, and customer data integration, catering to various sectors such as financial services, life sciences, government, and manufacturing. Founded in 2013 by experienced professionals in the database industry, Tamr is headquartered in Cambridge, Massachusetts, with additional offices in major cities including New York, Seattle, San Francisco, Washington, D.C., and London. The company aims to deliver valuable insights from data, supporting clients in achieving successful business outcomes.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Kensho Technologies, Inc. specializes in analytics, artificial intelligence, machine learning, and data visualization systems tailored for global banks and investment institutions. Founded in 2012 and headquartered in Cambridge, Massachusetts, with additional offices in New York, Virginia, and California, Kensho develops financial analytics software that enables scalable analytics solutions for commercial entities. Its offerings include Kensho Applied Mind, an AI software that enhances decision-making by addressing complex financial inquiries in natural language. The company also operates a national security division known as Koto. As of April 2018, Kensho operates as a subsidiary of S&P Global Inc.

GuideSpark, Inc. specializes in employee communication software aimed at enhancing engagement within organizations. Its primary offering, GuideSpark Communicate Cloud, allows human resource teams to implement communication campaigns and create multi-format content experiences that foster the adoption of HR programs. The platform addresses various HR challenges including benefits, performance management, and compensation. Additionally, GuideSpark provides resources for Total Rewards communication, talent management, and company culture communication, all designed to deepen employee appreciation for organizational investments and clarify their roles within the company. Founded in 2008 and headquartered in Redwood City, California, GuideSpark also has offices in Portland, Boston, San Francisco, and New York. The company serves over 1,000 enterprise customers, facilitating change communications that help align employee behavior with critical business objectives.

Philo is an entertainment-focused streaming service that provides live access to a variety of cable channels and major broadcasts, allowing users to enjoy shows, live news, sports, and entertainment on their smartphones or computers. The platform enables features such as pausing of live channels, enhancing the viewing experience. Originally founded to cater to the college market, Philo has evolved into a more comprehensive TV platform inspired by Philo T. Farnsworth, the inventor of electronic television. The company is headquartered in San Francisco, with additional offices in New York and Cambridge, Massachusetts. Philo has attracted investments from notable firms and individuals, including New Enterprise Associates, Rho Ventures, and HBO, which support its mission to create an improved television experience.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Solace Therapeutics, Inc. is a medical device company focused on developing non-surgical treatments for common bladder disorders, including stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company offers the Vesair Bladder Control System, a lightweight device designed to float within the urinary bladder and effectively reduce involuntary urinary leakage. Solace Therapeutics aims to enhance patient quality of life by providing an office-based therapy that avoids the side effects often associated with traditional drug and surgical options. This innovative approach does not require anesthesia or significant lifestyle changes and is reversible at any time. Established in 2002, Solace Therapeutics is headquartered in Framingham, Massachusetts.

Philo is an entertainment-focused streaming service that provides live access to a variety of cable channels and major broadcasts, allowing users to enjoy shows, live news, sports, and entertainment on their smartphones or computers. The platform enables features such as pausing of live channels, enhancing the viewing experience. Originally founded to cater to the college market, Philo has evolved into a more comprehensive TV platform inspired by Philo T. Farnsworth, the inventor of electronic television. The company is headquartered in San Francisco, with additional offices in New York and Cambridge, Massachusetts. Philo has attracted investments from notable firms and individuals, including New Enterprise Associates, Rho Ventures, and HBO, which support its mission to create an improved television experience.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics, catering to global enterprises. Founded in 2011 and headquartered in San Francisco, California, the company offers the SingleStore Managed Service, a cloud database-as-a-service that enables analytics on various cloud platforms, alongside SingleStore DB, a distributed SQL database suitable for both bare metal and hybrid cloud environments. The company focuses on operational analytics and supports modern data platform solutions that encompass IoT analytics, risk management, and customer engagement. SingleStore serves a diverse range of industries, including financial services, media communications, energy and utilities, government, and retail. The company, previously known as MemSQL Inc., rebranded to SingleStore, Inc. in October 2020 and also maintains offices in Seattle, Boston, Portland, Lisbon, and London.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient. Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.

Play Hard Sports, Inc. (Play Hard) is the first casual sports network in North America focused exclusively on developing, publishing and distributing exceptional sports games and entertainment across the Internet. Headquartered in the shadow of the world-famous football stadium at Foxboro, Massachusetts, Play Hard is creating the next-generation in online sports with no massive download, no long waiting for the game to load, and no required fees to play. Play Hard provides its audience with high-quality sports titles that can be played almost anywhere and anytime.

Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient. Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Play Hard Sports, Inc. (Play Hard) is the first casual sports network in North America focused exclusively on developing, publishing and distributing exceptional sports games and entertainment across the Internet. Headquartered in the shadow of the world-famous football stadium at Foxboro, Massachusetts, Play Hard is creating the next-generation in online sports with no massive download, no long waiting for the game to load, and no required fees to play. Play Hard provides its audience with high-quality sports titles that can be played almost anywhere and anytime.

Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.

Konarka Technologies, Inc. develops and advances nano-enabled polymer photovoltaic materials for commercial, industrial, government, and consumer applications. It provides standard products to serve portable power needs; and custom solutions, such as roll up chargers, personal accessories, and fold up chargers. The company's products are used in outdoor, portable power, indoor and remote sensing, and mission critical applications. It has strategic partnerships with Air Products, 24 Innovations, Kurz, SkyShades, Chevron, Merck, Toppan Forms, Dupont, Siemens, and the U.S. Air Force. Konarka Technologies, Inc. was founded in 2001 and is headquartered in Lowell, Massachusetts with business development offices in Asia. It has a research and development facility in Austria. The company has operations in the United States, Europe, and Asia.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.